chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient had pain in arm immediately after vaccine.  Patient thought the vaccine was given to high on arm.  Pain progressed that day.  Patient also developed golf-ball size lump and swelling at injection site.  Patient was unable to move arm by the end of day. Patient went to ER the next day.  2 days after the injection the swelling and pain had gone down but certain movements were still painful.  patient was contacted  12 days after immunization and arm was doing much better.
Skin rash and Urticaria, Pruritus. Treatment: Diphenhydramine 50 MG PRN, Triamcinolone 40 MG Once, Prednisone.
THE DAY FOLLOWING THE VACCINATION, THE PATIENT REPORTED HER ENTIRE ARM SWELLED AND WAS PAINFUL. SHE WAS ALSO RUNNING A TEMP. OF 102.2 (AT MD VISIT). THE PATIENT WAS ADMITTED TO THE HOSPITAL BY APRN ON 11/28/17 AND WAS DISCHARGED ON 12/4/17.
Arm soreness, headache day following vaccine. Two days following vaccine developed severe vulvar aphthous ulcer. Vulvar ulcerations have been recurrent following vaccination and are triggered by non-covid upper respiratory disease.
Fever to 102.4 and then siezure like activity for about 4 min. Baby then had a second episode of apnea.
Initially had the J and J vaccine in March 2021.  Had Moderna booster October 29, 2021.  Developed 3 PEs. Nine days after the booster.
Shortness of breath, severe bilateral knee pain (no history of knee issues or injury), lower extremity joint pain
Joint pain; sweating without fever/ Sweats; headache; Chills; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweating without fever/ Sweats), HEADACHE (headache), CHILLS (Chills), FATIGUE (fatigue) and ARTHRALGIA (Joint pain) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011M20A and 038A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concurrent medical conditions included Drug allergy and Seasonal allergy (grass, trees). Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) from 01-Jan-2020 to an unknown date for Allergy, DIHYDRALAZINE SULFATE, HYDROCHLOROTHIAZIDE, RESERPINE, TRIAMTERENE (NO 0), VITAMIN B COMPLEX from 01-Jan-2020 to an unknown date, ASCORBIC ACID, ROSA CANINA FRUIT (VITAMIN C & ROSEHIP) from 01-Jan-2020 to an unknown date and ZINC from 01-Jan-2020 to an unknown date for an unknown indication.   On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Feb-2021, the patient experienced HYPERHIDROSIS (sweating without fever/ Sweats), HEADACHE (headache), CHILLS (Chills) and FATIGUE (fatigue). On an unknown date, the patient experienced ARTHRALGIA (Joint pain). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (sweating without fever/ Sweats), HEADACHE (headache), CHILLS (Chills), FATIGUE (fatigue) and ARTHRALGIA (Joint pain) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Dec-2020, COVID-19: positive (Positive) positive.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Treatment details included Ibuprofen.   This case was linked to MOD-2021-096361 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Apr-2021: Reporter information, Patient demographics, allergic conditions, concomitant medicines and an event were updated.
tested positive for the virus; tested positive for the virus; This is a spontaneous report from a Pfizer sponsored program. A non-contactable Male consumer reported for himself that or other non healthcare professional. A male patient of an unspecified age received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1st dose, single dose for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient underwent lab tests and procedures which included sars-cov-2 test: positive. The patient tested positive for the virus (sars-cov-2 test positive) on an unspecified date. INT-# Swap from (Name)- first time caller received his first covid vaccine and then tested positive for the virus. He was suppose to get his second covid vaccine and was now wondering if he should still get it. Upon collecting his information (only got his name) for transfer he stated his work was calling for conference call and he had to get off the phone. Provided him medical information to call later.   Medical Information: Were any unaddressed medical questions referred or forwarded to Medical Information: No  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
arm pain in side of pneumovax;arm swollen dx cellulitis rx ATB orally  fever;
very painful arm and armpit with red splotches and inflammation all the way down the arm to the fingers initially.  patient prescribed keflex and medrol dosepak for diagnosis of cellulitis.  pain has gone down and patient still has slight itching, less redness, and better movement in the arm
Experienced memory loss; Memory loss which continued into the next morning with confusion; This non-serious case was reported by a nurse via call center representative and described the occurrence of confusion in a 87-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 9By32, expiry date 11-MAY-2024) for prophylaxis.   On 03-SEP-2023, the patient received Arexvy (left deltoid). In SEP-2023, an unknown time after receiving Arexvy, the patient experienced confusion (Verbatim: Memory loss which continued into the next morning with confusion) and memory loss (Verbatim: Experienced memory loss).  In SEP-2023, the outcome of the memory loss was resolved. The outcome of the confusion was unknown.   It was unknown if the reporter considered the confusion and memory loss to be related to Arexvy.     It was unknown if the company considered the confusion and memory loss to be related to Arexvy.   Additional Information: GSK Receipt Date: 14-SEP-2023. The reporter stated that the wife of the patient called the reporter on September 7, 2023.     After the patient received the vaccine, the patient experienced memory loss which continued into the next morning with confusion.   It took about 3 hours before the patient could remember everything. The reporter provide the lot number for Arevy, but this does match the product. The patient received the vaccine at a pharmacy. The reporter consented to follow up.
Pt call on the Nov 13 complaining of severe muscle aches in the neck, back and shoulders with a pain of 7 out of 10. His symptoms began 6 days post administration. And 9 days after the shot pt develpoed a rash on the right side of his chest
WITHIN 12 HOURS:  SEVERE DROWSINESS; 24 HOURS:  VERTIGO, DIZZINESS; 36 HOURS:  NUMBNESS & TINGLING LEFT ARM, SHORTNESS OF BREATH, FATIGUE  48 HOURS: LOSS OF COORDINATION OF LEFT ARM WITH CONTINUED NUMBNESS & TINGLING.  WENT TO EMERGENCY ROOM AND WAS SUBSEQUENTLY ADMITTED. RULED OUT TIA, STROKE, TUMOR, PINCHED NERVE.  BRAIN CT, MRI, MRA, ECHO AND EKG ALL WNL.  72 HOURS: LEFT ARM NUMBNESS & TINGLING GONE, BUT SLIGHT WEAKNESS REMAINS, EXTREME DROWSINESS & FATIGUE CONTINUE. DISCHARGED FROM HOSPITAL.  INCONCLUSIVE AS TO CAUSE FOR NUMBNESS, TINGLING AND DIZZINESS.  6/2/09 Hospital records received DOS 5/2/09 to 5/3/09. FINAL DIAGNOSIS: Transient Ischemic Attack. Post vaccination presented with numbness left arm, dropped bowl of cereal earlier that day. Weak, dizziness, headache. Neurological consult - hypoesthesia left upper extremity. ICD-9 Code: 435.9 Trans Cereb Ischemia NO.
Patient's father came in; said patient felt ill, went to emergency room, got hospitalized for respiratory problem/infection and died day(?) shortly afterward. 11/20/06 Received medical records from hospital which indicate patient seen 10/13/06 with altered mental status, SOB, nausea, vomiting.  Seen in local clinic & dx w/HTN.  Patient coded outside ER where he had been brought by his parents.  Code/intubation were successful.  NGT revealed coffee ground gastric contents. LABS: WBC 41,800, H/H 9.3/26.3, plts 119,000.  Na 110, K5.5, BUN/creat 108/3.9, cl 76.  Troponin 0.16.  Calcium 5.7.  Beta natriuretic peptide 1570. ABG showed metabolic acidosis.  CXR revealed cardiomegaly w/pulmonary congestion consistent w/CHF & RLL pneumonia.   Patient expired 10/23/06 when he coded again while on his way to OR for trach. No autopsy was done. DX: cardiopulmonary arrest s/p successful resuscitation; Gram neg septic shock, acute renal failure; metabolic acidosis; hypocalcemia; ARDS; multi system organ failure; & UGI bleeding. 12/1/06 Received death certificate which reveals COD as acute cardiopulmonary arrest, septic shock & hypertension.
Initial rash, hot to touch, swollen, painful.  Returned 9 days later with same symptoms, hot to touch, painful, very itchy, large red circle at injection site.
Client was at clinic for a Pfizer covid booster, had previously had an Astrazeneca series completed 08/23/2021. At the time of administration she was A&O, in no apparent distress. Client was primarily different language speaking, interpreter was in the room with this RN. Reported no allergies at the time of screening. Reported a rash on her chest from a previous dose of Astrazeneca, but was not sure if it was r/t the vaccine. RN administered the Pfizer booster IM in the R deltoid and provided a new vaccine card.  Client went to the lobby area to wait the 15 minute observation period.  Approximately 2 -3 minutes later, client c/o tightness in her throat. Client was assessed by this RN. She was A&Ox3, denied SOB, dyspnea and any GI symptoms. There was no rash on her upper body and no c/o pruritus. HR was in the normal range, her O2 saturation was also normal 93 - 96% (checked on her apple watch). She coughed a couple of times during this period. Client was observed for more than 30 minutes.  She declined to have EMS called. Her husband was called and arrived shortly after. We explained our concerns about a possible allergic reaction and strongly encouraged him to take his wife to the ED at Hospital.  They left the clinic about 4:45 pm. RN, RN and RN were at the clinic during this event and consulted.
1hr to 2hr post vax mouth dry, tongue sensitive, swollen around jaw;small lumps on inside of mouth;
Vaccine received at 3:29 pm on 12/26/2020. By 4:00 pm she had complaints of a headache, dizziness alog with nausea and vomiting. S/S without resolution or decrease. Sent to Emergency Department for evaluation at 5:35 pm. She was administered  the follwing @ 5:39 Sodium Chloris IV,  6:18 pm 1,000 mg IV tylenol, ketorolac 30 mg IV push and Ondansetron 4 mg IV. She was discharged no longer nauseated and headache decreased from a 4 to a 2. discharged in stable condition.  on 12/27/2020 she stated she had fatigue, nausea and vomiting, diarrhea and a temp os 102.0. 12/28/2020 N/V, diarrhea and fever resolved. C/o's joint pain and body aches.
Lost of taste after first covid vaccine; This spontaneous case was reported by a patient and describes the occurrence of AGEUSIA (Lost of taste after first covid vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced AGEUSIA (Lost of taste after first covid vaccine). At the time of the report, AGEUSIA (Lost of taste after first covid vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant and Treatment medications were not provided by reporter.
J96.00 ACUTE RESPIRATORY FAILURE 8/25/2022 METABOLIC ENCEPHALOPATHY J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/25/2022 METABOLIC ENCEPHALOPATHY J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 6/6/2022 METABOLIC ENCEPHALOPATHY J96.10 CHRONIC RESPIRATORY FAILURE 4/25/2022 METABOLIC ENCEPHALOPATHY J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 8/23/2022 METABOLIC ENCEPHALOPATHY R09.02 HYPOXIA 4/25/2022 METABOLIC ENCEPHALOPATHY J96.00 ACUTE RESPIRATORY FAILURE 8/25/2022 DIASTOLIC HEART FAILURE, ACUTE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/25/2022 DIASTOLIC HEART FAILURE, ACUTE J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 6/6/2022 DIASTOLIC HEART FAILURE, ACUTE J96.10 CHRONIC RESPIRATORY FAILURE 4/25/2022 DIASTOLIC HEART FAILURE, ACUTE J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 8/23/2022 DIASTOLIC HEART FAILURE, ACUTE R09.02 HYPOXIA 4/25/2022 DIASTOLIC HEART FAILURE, ACUTE J96.00 ACUTE RESPIRATORY FAILURE 8/25/2022 ATRIAL FIBRILLATION, PAROXYSMAL J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/25/2022 ATRIAL FIBRILLATION, PAROXYSMAL J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 6/6/2022 ATRIAL FIBRILLATION, PAROXYSMAL J96.10 CHRONIC RESPIRATORY FAILURE 4/25/2022 ATRIAL FIBRILLATION, PAROXYSMAL J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 8/23/2022 ATRIAL FIBRILLATION, PAROXYSMAL R09.02 HYPOXIA 4/25/2022 ATRIAL FIBRILLATION, PAROXYSMAL
MMR-II titer done in 1982 for her nursing school which was negative / titer done in February of 2019 for her empleyment and her titers were negative again; MMR-II titer done in 1982 for her nursing school which was negative, and was vaccinated again with MMR-II (third vaccination); This spontaneous report was received from a consumer who was also a nurse, concerning about herself, a currently 57-year-old female patient.      No information was provided regarding the patient's concurrent conditions, medical history, past drug reactions / allergies or concomitant medications.      On an unknown date, the patient was vaccinated with the first dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II). On an unspecified date in 1978, she had a booster of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), because her mother was pregnant. On an unspecified date in 1982, a measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) titer was done for her nursing school which was negative (antibody test negative), and she was vaccinated again with MMR-II (third vaccination) (overdose). On an unspecified date in February 2019, another measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) titer was done for her employment and her titers were negative again (antibody test negative), therefore, she was vaccinated again with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) on 01-MAY-2019, due to negative titer. All measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) vaccines were administered as prophylaxis (strengths, doses, routes of administration, lots number and dates of expiration were not provided). It was reported that the patient received treatment (unspecified) for the event. No product quality complaint was filed.  The causality assessment between the event antibody test negative, and the suspect vaccine was not provided.
Dose 1:  Light headed, asthmatic light breathing after 10 mins.  mild headache within 1 hour.  Extreme Headache lasted 4 days intensified after first full day, arm tenderness 5 days  Dose 2:  Light headed, extreme nausea, heat flush, redness in face within 5-15 mins of shot.  Continuous nausea, no appetite for 18 hours; first evening sever fatigue full body aches, low mobility in legs, serve chills and extreme headache; second day nausea improved, fatigue, body aches, chest tightening, intermittent headache - treated with Advil.  Evening fatigue, chest tightening, chills
onset of tingling on both hands... pain in legs... muscle weakness... unsteadiness... loss of reflex in major tendons... eyeballs hurt (eye pain). Loss of coordination.
Fever; Chills; Nausea; Loss of appetite; Taste altered; Headache; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er26213) via an unspecified route of administration in the arm left on 19Mar2021 at 14:15 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. The patient had no known allergies. The patient did not receive any concomitant medications. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Mar2021 at 18:00, the patient experienced fever, chills, nausea, loss of appetite, taste altered and headache. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, nausea, loss of appetite, taste altered and headache was recovered in Mar2021 (unspecified date).  No follow-up attempts are needed. No further information is expected.
HIVES; FATIGUE; FEVER; BODY ACHES; CHILLS; This spontaneous report received from a patient concerned a 33 year old female. The patient's height, and weight were not reported. The patient's past medical history included covid-19, and concurrent conditions included shellfish allergy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and batch number: 042A21A expiry: 21-JUN-2021) dose was not reported, administered on 01-APR-2021 at right arm for prophylactic vaccination. No concomitant medications were reported.  On 01-APR-2021, the subject experienced body aches. On 01-APR-2021, the subject experienced chills. On 01-APR-2021, the subject experienced fatigue. On 01-APR-2021, the subject experienced fever. Treatment medications included: ibuprofen. On 03-APR-2021, the subject experienced hives. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills, and fever on 03-APR-2021, was recovering from fatigue, and body aches, and had not recovered from hives. This report was non-serious.
Herpes Zoster; Varicella Information has been received from a physician concerning her healthy 17 year old daughter with an allergy to cefaclor (Ceclor) who "15 years ago" at the "age of two" in "approximately 1990" was vaccinated with a 0.5ml subcutaneous dose of varicella virus vaccine live (Oka/Merck). There was no concomitant medication. "At age 5" in approximately 1993, the patient was exposed to chicken pox and developed a few lesions. Then, on 08-SEP-2005, the patient complained of shoulder pain. On 10-SEP-2005 she developed zoster on her arm with pain and burning. At the time of the report the patient was receiving acyclovir therapy and had broken out in two new areas wit the last 24 hours. At the time of the report it was noted that the patient had not recovered. No product quality complain was involved. No other information was provided. Follow-up information from a physician indicated that the patient developed full blown shingles, one dermatome, described as a classic rash with pain and neuralgia. It was also noted the patient had fluid filled vesicles and was pretty uncomfortable. Follow-up information from a physician indicated that the patient had a recent exposure to shingles from a classmate in school. It was also noted that a vesicle was obtained for VZV identification. Follow-up information from a physician indicated on 14-AUG-2005 a lesion was obtained for VZV identification and VZV DNA was amplified. The interpretation was that it was an adequate specimen wild type strain. On 16-SEP-2005 a lesion was obtained for VZV identification and no VZV DNA or B-globin DNA was amplified and it was interpreted to be an inadequate specimen, negative for B-globin, no strain identification. Additional information has been requested.
Patient COVID vaccine dose administered on 12/13/21 past the expiration/beyond-use date. Per manufacturer patient is to repeat the dose immediately. Patient is notified. They will consider repeat dose.
About eight hours after I was vaccinated, I began to experience fatigue and full body ache. I went to bed around 6:30 pm, and I was violently trembling with chills for hours. The body aches became as bad as I have ever experienced, and, although I was lying still in bed,  my heart rate was alarmingly high for most of the night --around midnight my heart rate was 120 bpm. My usual resting heart rate is in the 60s. It continued to be very high, and it got as high as 130 bpm between 1 a.m. and 6 a.m. Meanwhile, I felt like I had a fever (although I couldn't find a thermometer). I drank a lot of water during the night hoping it would help my heart rate go down. I put a cold cloth on my forehead, and I took four Advil around 4 a.m.  My body aches and elevated heart (90-110 bpm) rate continued throughout the next day. My heart rate finally came down during the following night, and fatigue and body aches dissipated over the following day.
No other AE occurred; Expired vaccine used; This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history, historical drug and concomitant therapies were not reported.  On 27-JAN-2022, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent(ROTATEQ), lot # 1707415, expiration date : 18-JAN-2022 (dose, route of administration and anatomical location) for prophylaxis. (expired product administered). No other adverse event occurred.
deep vein thrombosis in left leg due to complaints of pain and swelling in left leg.  Pt received apixaban and Xarelto to treat DVT.   Pt stopped blood thinners due to repeated nose bleeds.  Pt reported decreased swelling and absence of pain in left leg at present.
first dose of BNT162B2:19Dec2020 ; second dose of BNT162B2: 05Jan2021; first dose of BNT162B2:19Dec2020 ; second dose of BNT162B2: 05Jan2021; hearing loss; This is a spontaneous report from a non-contactable consumer (patient). A 57-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EJ1686), via unspecified route of administration on 05Jan2021 (at the age of 57 years) at a single dose in the left arm for COVID-19 immunization. Medical history included 'hypothyroid'. Concomitant medication included levothyroxine. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK5730) on 19Dec2020 at 11:00 AM (age: 57-years) in the left arm for COVID-19 immunization. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior vaccination. The patient was not pregnant at the time of vaccination. On 06Jan2021 at 16:00, the patient had hearing loss. The event resulted to physician office visit. The patient received steroids as treatment. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.